Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
people
CFOs On the Move: Week Ending June 2
Pinterest, TransDigm Group, United Airlines, Organic Valley, Nestle, Unilever, Prudential, Alltrust Credit Union
By
CFO Editorial Staff
| June 2, 2023
Read More
Resources
Reports
Reports
2023
2022
Featured
people
CFOs On the Move: Week Ending June 2
Pinterest, TransDigm Group, United Airlines, Organic Valley, Nestle, Unilever, Prudential, Alltrust Credit Union
By
CFO Editorial Staff
| June 2, 2023
Read More
Sign Up
Menu
Reports
2023
2022
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
Sign Up
Sponsored by
Valeant
Risk & Compliance
Regulator Bars Valeant Officers From Trading
A Canadian regulator issues a cease trade order after the troubled drug maker announces it would be late filing financial reports.
By
Katie Kuehner-Hebert
| April 1, 2016
Read More
Risk & Compliance
Ex-Valeant CFO Denies ‘Improper Conduct’
Howard Schiller says he is not to blame for the incorrect recognition of $58 million in revenue that has caused Valeant to restate its financial results.
By
Katie Kuehner-Hebert
| March 21, 2016
Read More
Regulation
Valeant Discloses SEC Probe
The pharmaceuticals company also canceled its 2016 financial guidance and delayed filing its fourth-quarter earnings report.
By
Matthew Heller
| March 1, 2016
Read More
M&A
Roll-ups: Serial Thrillers
The agonies and ecstasies of firms that are addicted to doing takeovers.
By
Economist Staff
| December 21, 2015
Read More
Risk
Ackman’s Allergan Takeover Bid Is Easier Said Than Done
The takeover contest's outcome becomes unclear when we consider the conflict between the hedge fund’s objectives and the Allergan board's fiduciary duty.
By
Gardner Davis
| June 16, 2014
Read More
